Capital Cell for Companies
Close your investment round faster
Capital Cell is the world's leading alternative investment platform for biotechnology and life sciences companies.
We are a financial institution authorized on the basis of the European Regulation 2020/1503 on Crowdfunding Service Providers, acting under the supervision of the European financial market authorities.
We select the most promising biomedical innovation investment opportunities across Europe, helping them connect with investors in an agile way so they can focus on developing their businesses.
The investment community of Capital Cell
Registered investors
Investment rounds
via crowdfunding
Average round size
per investor
Successfully closed rounds
How do we do it?
The basic steps for an investment round.
- You share your pitch deck.
- Our network of expertsBioExpert Network) evaluates your company.
- A Lead Investor leads your investment round.
- The committee of Capital Cell analyzes and approves your proposal.
- Due diligence is completed and the campaign is prepared.
- Start of the pre-campaign for your network and our investors.
- Public campaign on our website.
- You reach your goal, we close the campaign and you receive the money.
At Capital Cell we work as a team, we only get paid if you win too.
How much does it cost to raise a round of financing with Capital Cell?
Included in the round free of charge
- Analysis and report of the BioExpert Network.
- Crowdfunding consulting and personalized advice.
- Communication and promotion of the campaign among our network of investors.
- Strategic financial consulting: round structure, investment objective, valuation, etc.
- Analysis & technical and market due diligence.
- Legal and financial due diligence.
- Escrow account and payment gateway.
Not included in the round
Publication on the
platform: €1,500
Crowdfunding campaign:
- Competitive commission on funds raised: 8%
- At Capital Cell we do not charge commission for previously agreed investments.
Additional services:
- We can offer you a complete marketing and communication service: Video, PR (press, events), banners, infographics, advertising on social networks and professional networks, just ask us!
- Legal services before and after the round: check prices according to your needs
Send us your investment opportunity
Send us your pitch deck and we will evaluate it with our team of experts.
Companies that have already achieved their goals
Extensive experience of successfully completed rounds. Check our track record.
After raising nearly 2 million euros, Bionure Accure Therapeutics in 2020; in 2022, it signed a licensing agreement with Occulis worth more than 900 million euros for its optic neuritis drug, OCS-05.
Vytrus public in March 2022 and became the fastest-growing stock on the Spanish stock market in 2025, giving investors an indicative investment multiple of x17.
GoodGut's diagnostic and therapeutic technology for digestive diseases continues development and commercialization after its sale to HIPRA.